Nabriva Therapeutics plc

(NBRV) Trade

By |

Profile

Nabriva Therapeutics AG is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company is developing product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections.

Contact Information

Website: www.nabriva.com
Email: david.garrett@nabriva.com
Main Phone: +353 16492000
Address: 25-28 North Wall Quay
Address 2: IFSC
City / Town: Dublin
Country: IRL
Postal Code: 1

Issuer Information

Exchange: NGS
CEO: Theodore R. Schroeder
Employees: 88
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)
$ 2.08 $ 0.02 (0.97%)
Last Price 2.08 Change $ 0.02 Change % 0.97 Tick N/A
Bid 2.08 Bid Size 200.00 Ask 2.09 Ask Size 400.00
Open 2.09 High 2.11 Low 2.06 Prev Close 2.06
Last Trade Volume 77,767 52 Wk Hi 6.94 52 Wk Low 1.84
Market Cap 139.3 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 66,982,094.00 EPS (TTM) -2.30 PE Ratio N/A Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 5 8
Number of Buys 5 8
Number of Sells 0 0
Net Activity 32160 38098
Last 10 Buys Shares
Robert Crotty 1,000
Colin Broom 1,000
Stephen W. Webster 1,000
Gary L. Sender 1,000
Francesco Maria Lavino 1,000
Gary L. Sender 1,000
Colin Broom 1,000
Last 10 Sell Shares
N/A 0
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 22 22 22 22
Low Target Price Estimate 9 9 9 9
Mean Target Price Estimate 16.36 16.36 16.17 16.36
Standard Deviation 4.77 4.77 5.19 4.77
Date of Most Recent Estimate 05/31/18 05/31/18 05/23/18 05/31/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 7 6 6 4
Moderate Buy 0 0 1 1
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1 1 1.07 1.1